News & Updates
Filter by Specialty:
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
byRoshini Claire Anthony
Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.
Bimekizumab triumphs in bDMARD-naïve psoriatic arthritis patients
20 Jun 2022
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
20 Jun 2022
Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.
Vunakizumab safe, effective in moderate-to-severe plaque psoriasis
20 Jun 2022
RELIEVE-AD: Atopic dermatitis patients see rapid, sustained improvements with dupilumab
17 Jun 2022
byJairia Dela Cruz
The biologic dupilumab appears to be a hit with atopic dermatitis (AD) patients treated in the real-world setting, with patients experiencing prompt improvements in multiple aspects of disease control that persisted through 1 year, as shown in the results of the RELIEVE-AD* study.
